Nanobiotix (NASDAQ:NBTX) reported complete Phase 1 full-cohort results for radiotherapy-activated JNJ-1900, formerly NBTXR3, in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation.
Takeda (NYSE:TAK) said the U.S. FDA accepted its New Drug Application for zasocitinib under Priority Review for adults with moderate-to-severe plaque psoriasis.
Novo Nordisk (NYSE:NVO) launched a corporate rebrand that will see the company use the shorter “Novo” name in day-to-day communications while retaining Novo Nordisk A/S as its legal name.
Clearmind Medicine (NASDAQ:CMND) enrolled the first two patients with Alcohol Use Disorder in its ongoing clinical trial of CMND-100, a non-hallucinogenic psychedelic-derived drug candidate.
Eloxx Pharmaceuticals (NASDAQ:ELOX) dosed the first two patients in the EXACT Study, a Phase 2b clinical trial evaluating exaluren in patients with nonsense mutation Alport syndrome.
NRx Pharmaceuticals (NASDAQ:NRXP) announced that its subsidiary HOPE Therapeutics has started deploying Zeta Surgical’s FDA-cleared robotic TMS system at Florida clinics.
Bausch + Lomb (NYSE:BLCO) received European CE Mark approval for SeeLyra, a next-generation femtosecond laser platform designed for ophthalmic surgical procedures.
Perspective Therapeutics (NYSE:CATX) announced that updated data from its [212Pb]VMT-α-NET program have been accepted for presentation at the 38th EORTC-NCI-AACR Symposium in Barcelona.
Jaguar Health (NASDAQ:JAGX) reported that all randomized pediatric patients with microvillus inclusion disease have entered the single-blind extension phase of Napo Pharmaceuticals’ pivotal crossover trial evaluating crofelemer.
AbbVie (NYSE:ABBV) reported positive Phase 3 LUNA trial topline results for atogepant, showing reduced migraine days in women with menstrual migraine.
CAMP4 Therapeutics (NASDAQ:CAMP) received authorization from the UK Medicines and Healthcare products Regulatory Agency to include United Kingdom sites in its planned global Phase 1/2 clinical trial of CMP-002 for SYNGAP1-related disorder.
CervoMed (NASDAQ:CRVO) announced that neflamapimod will be featured in a late-breaking oral presentation at the International Society of Frontotemporal Dementias Annual Meeting in October 2026.
